CXL-1020

CXL-1020, a proprietary compound generated by Cardioxyl's nitroxyl chemistry platform, has recently completed a Phase IIa clinical trial in acute decompensated heart failure. More information is available on CXL-1020 clinical trials.

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.